This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by de Gaetano, G. Articles by Latini, R. Search for Related Content PubMed PubMed Citation Articles by de Gaetano, G. Articles by Latini, R.

Circulation, Vol 72, 1185-1193, Copyright © 1985 by American Heart Association

ARTICLES

Pharmacology of platelet inhibition in humans: implications of the salicylate-aspirin interaction

G de Gaetano, C Cerletti, E Dejana and R Latini

The current dispute over the effects of "low" vs "high" doses of aspirin should take into consideration the pharmacokinetics of this drug. In fact, different pharmaceutical formulations of aspirin may deliver little or no aspirin to the systemic blood. This was the case, for instance, in healthy volunteers taking 320 mg of compressed aspirin or 800 mg of enteric-coated aspirin. In all instances thromboxane B2 generation in serum was fully inhibited. Platelet cyclooxygenase might therefore be effectively acetylated by exposure to aspirin in the portal circulation, whereas vascular cyclooxygenase could be spared. Thus aspirin formulations ensuring complete first-pass deacetylation should be sought rather than "low" or "high" doses of unspecified aspirin formulations. Regardless of the type and dose of aspirin administered, salicylate is formed and accumulates in the circulation. It may antagonize the effects of aspirin on cyclooxygenase, at least in acute conditions. As an example, after administration of 1 g of salicylate to healthy volunteers, when plasma levels of the drug were about 75 micrograms/ml, the effect of 40 mg iv aspirin (given 40 min later) on platelet cyclooxygenase and aggregation was significantly diminished. In contrast, in patients undergoing saphenectomy, the same dose of salicylate (1 g) gave plasma drug levels of about 25 micrograms/ml; salicylate was unable to prevent the inhibitory effect on platelets of 40 mg iv aspirin (given 1 hr later) but did act on vascular prostacyclin. Thus the combination of salicylate with aspirin at an appropriate dose and blood level ratio may result in almost complete dissociation of the drug's effect on platelets and vessels in man.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				Y. Birnbaum, Y. Lin, Y. Ye, J. D. Martinez, M.-H. Huang, C. Y. Lui, J. R Perez-Polo, and B. F. Uretsky Aspirin before reperfusion blunts the infarct size limiting effect of atorvastatin Am J Physiol Heart Circ Physiol, June 1, 2007; 292(6): H2891 - H2897. [Abstract] [Full Text] [PDF]

				T. Corazzi, M. Leone, R. Maucci, L. Corazzi, and P. Gresele Direct and Irreversible Inhibition of Cyclooxygenase-1 by Nitroaspirin (NCX 4016) J. Pharmacol. Exp. Ther., December 1, 2005; 315(3): 1331 - 1337. [Abstract] [Full Text] [PDF]

				I Ikonomidis, F Andreotti, and P Nihoyannopoulos Reduction of daily life ischaemia by aspirin in patients with angina: underlying link between thromboxane A2 and macrophage colony stimulating factor Heart, April 1, 2004; 90(4): 389 - 393. [Abstract] [Full Text] [PDF]

				C. Patrono, B. Coller, J. E. Dalen, G. A. FitzGerald, V. Fuster, M. Gent, J. Hirsh, and G. Roth Platelet-Active Drugs : The Relationships Among Dose, Effectiveness, and Side Effects Chest, January 1, 2001; 119 (2009): 39S - 63S. [Full Text] [PDF]

				A. A. Shehadeh, J. Arena, C. B. Moschos, and T. J. Regan Nonplatelet Effects of Aspirin During Acute Coronary Occlusion: Electrophysiologic and Cation Alterations in Ischemic Myocardium Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 2000; 5(2): 113 - 120. [Abstract] [PDF]

				I. Ikonomidis, F. Andreotti, E. Economou, C. Stefanadis, P. Toutouzas, and P. Nihoyannopoulos Increased Proinflammatory Cytokines in Patients With Chronic Stable Angina and Their Reduction By Aspirin Circulation, August 24, 1999; 100(8): 793 - 798. [Abstract] [Full Text] [PDF]

				L. Chen, M. N. Salafranca, and J. L. Mehta Cyclooxygenase inhibition decreases nitric oxide synthase activity in human platelets Am J Physiol Heart Circ Physiol, October 1, 1997; 273(4): H1854 - H1859. [Abstract] [Full Text] [PDF]

				A. Lopez-Farre, A. Riesco, E. Digiuni, J. R. Mosquera, C. Caramelo, L. S. de Miguel, I. Millas, T. de Frutos, M. R. Cernadas, M. Monton, et al. Aspirin-Stimulated Nitric Oxide Production by Neutrophils After Acute Myocardial Ischemia in Rabbits Circulation, July 1, 1996; 94(1): 83 - 87. [Abstract] [Full Text]

				N. F. Col, J. Yarzebski, J. M. Gore, J. S. Alpert, and R. J. Goldberg Does Aspirin Consumption Affect the Presentation or Severity of Acute Myocardial Infarction? Arch Intern Med, July 10, 1995; 155(13): 1386 - 1389. [Abstract] [PDF]

				I. A. Alhaddad, L. Tkaczevski, F. Siddiqui, R. Mir, and E. J. Brown Jr Aspirin Enhances the Benefits of Late Reperfusion on Infarct Shape : A Possible Mechanism of the Beneficial Effects of Aspirin on Survival After Acute Myocardial Infarction Circulation, June 1, 1995; 91(11): 2819 - 2823. [Abstract] [Full Text]

				A. Lopez-Farre, C. Caramelo, A. Esteban, M. L. Alberola, I. Millas, M. Monton, and S. Casado Effects of Aspirin on Platelet-Neutrophil Interactions : Role of Nitric Oxide and Endothelin-1 Circulation, April 1, 1995; 91(7): 2080 - 2088. [Abstract] [Full Text]

				C. Kearon and J. Hirsh Optimal Dose for Starting and Maintaining Low-Dose Aspirin Arch Intern Med, March 22, 1993; 153(6): 700 - 702. [Abstract] [PDF]